334 related articles for article (PubMed ID: 30504510)
1. Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.
Hagen M; Englbrecht M; Haschka J; Reiser M; Kleyer A; Hueber A; Manger B; Figueiredo C; Cobra JF; Tony HP; Finzel S; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Lorenz HM; Nüsslein H; Alten R; Henes J; Krüger K; Schett G; Rech J
J Rheumatol; 2019 May; 46(5):460-466. PubMed ID: 30504510
[TBL] [Abstract][Full Text] [Related]
2. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.
Rech J; Hueber AJ; Finzel S; Englbrecht M; Haschka J; Manger B; Kleyer A; Reiser M; Cobra JF; Figueiredo C; Tony HP; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Lorenz HM; Nuesslein H; Alten R; Henes J; Krueger K; Schett G
Ann Rheum Dis; 2016 Sep; 75(9):1637-44. PubMed ID: 26483255
[TBL] [Abstract][Full Text] [Related]
3. ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation.
Boeters DM; Burgers LE; Sasso EH; Huizinga TWJ; van der Helm-van Mil AHM
Arthritis Res Ther; 2019 May; 21(1):121. PubMed ID: 31088574
[TBL] [Abstract][Full Text] [Related]
4. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
[TBL] [Abstract][Full Text] [Related]
5. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
[TBL] [Abstract][Full Text] [Related]
6. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.
Boeters DM; Burgers LE; Toes RE; van der Helm-van Mil A
Ann Rheum Dis; 2019 Nov; 78(11):1497-1504. PubMed ID: 31413004
[TBL] [Abstract][Full Text] [Related]
7. Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs.
de Moel EC; Rech J; Mahler M; Roth J; Vogl T; Schouffoer A; Goekoop RJ; Huizinga TWJ; Allaart CF; Toes REM; Schett G; van der Woude D
Arthritis Res Ther; 2019 Dec; 21(1):268. PubMed ID: 31805992
[TBL] [Abstract][Full Text] [Related]
8. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
Bouman CAM; van der Maas A; van Herwaarden N; Sasso EH; van den Hoogen FHJ; den Broeder AA
Rheumatology (Oxford); 2017 Jun; 56(6):973-980. PubMed ID: 28339738
[TBL] [Abstract][Full Text] [Related]
9. The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis.
Shafrin J; Tebeka MG; Price K; Patel C; Michaud K
J Manag Care Spec Pharm; 2018 Jan; 24(1):4-11. PubMed ID: 29290168
[TBL] [Abstract][Full Text] [Related]
10. Does the presence of magnetic resonance imaging-detected osteitis at diagnosis with rheumatoid arthritis lower the risk for achieving disease-modifying antirheumatic drug-free sustained remission: results of a longitudinal study.
Burgers LE; Boeters DM; Reijnierse M; van der Helm-van Mil AHM
Arthritis Res Ther; 2018 Apr; 20(1):68. PubMed ID: 29636084
[TBL] [Abstract][Full Text] [Related]
11. Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution.
Verstappen M; van Steenbergen HW; de Jong PHP; van der Helm-van Mil AHM
Arthritis Res Ther; 2022 Jan; 24(1):4. PubMed ID: 34980246
[TBL] [Abstract][Full Text] [Related]
12. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission.
El Miedany Y; El Gaafary M; Youssef S; Ahmed I; Bahlas S; Hegazi M; Nasr A
Clin Rheumatol; 2016 Dec; 35(12):2915-2923. PubMed ID: 27658417
[TBL] [Abstract][Full Text] [Related]
13. Ability to predict rheumatoid arthritis relapse after tumour necrosis factor inhibitor tapering by the Multi-Biomarker Disease Activity Score: a post-hoc analysis of the STRASS trial.
Moysidou GS; Marotte H; Kossi S; Tubach F; Hajage D; Fautrel B
Clin Exp Rheumatol; 2023 Sep; 41(9):1831-1837. PubMed ID: 37497730
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial.
Brahe CH; Østergaard M; Johansen JS; Defranoux N; Wang X; Bolce R; Sasso EH; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll C; Jørgensen A; Krintel SB; Raun J; Hetland ML
Scand J Rheumatol; 2019 Jan; 48(1):9-16. PubMed ID: 29985080
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept.
Neubauer AS; Minartz C; Herrmann KH; Baerwald CGO
Clin Exp Rheumatol; 2018; 36(3):448-454. PubMed ID: 29303709
[TBL] [Abstract][Full Text] [Related]
16. Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care.
Burgers LE; van der Pol JA; Huizinga TWJ; Allaart CF; van der Helm-van Mil AHM
Arthritis Res Ther; 2019 May; 21(1):115. PubMed ID: 31064384
[TBL] [Abstract][Full Text] [Related]
17. Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment.
Ghiti Moghadam M; Lamers-Karnebeek FBG; Vonkeman HE; Ten Klooster PM; Tekstra J; Schilder AM; Visser H; Sasso EH; Chernoff D; Lems WF; van Schaardenburg DJ; Landewe R; Bernelot Moens HJ; Radstake TRDJ; van Riel PLCM; van de Laar MAFJ; Jansen TL;
PLoS One; 2018; 13(5):e0192425. PubMed ID: 29791439
[TBL] [Abstract][Full Text] [Related]
18. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.
Kjørholt KE; Sundlisæter NP; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Kvien TK; Solomon DH; van der Heijde D; Haavardsholm EA; Lillegraven S
Lancet Rheumatol; 2024 May; 6(5):e268-e278. PubMed ID: 38583450
[TBL] [Abstract][Full Text] [Related]
19. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
20. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
